10.30.26 -- Printing A New Path To The Brain: 3D Buccal Nanofilms For CNS Lymphoma

Three factors often decide success or failure in FIH studies: integrating biomarkers and pharmacodynamic endpoints, including patients in the trials, and leveraging manufacturing infrastructure.

Manufacturers must cut decision delays, harness AI to unlock data, embrace adaptive automation, and empower teams to act as force multipliers. See how these shifts define the path to resilience.

Explore trends and challenges in microbiology QC with Anne Weeks, a senior field marketing manager. She discusses workflow automation and introduces a customizable MTR solution.

Spray dry technology is being leveraged to create shelf-stable, dry-powder vaccines to treat and prevent the spread of tuberculosis which could significantly improve our global response to disease.

Effective cleanroom management requires moving beyond checkbox compliance. Learn how to empower your workforce by connecting individual roles to broader contamination control goals.

Achieve continuous regulatory readiness by embedding ALCOA++ compliance directly into manufacturing workflows to eliminate paper-based documentation risks.

Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.

Wellington Foods ensures dietary supplement safety using an X-ray system, which detects contaminants, and meets regulatory standards with high-speed, precise inspection technology.

Amid the mRNA and oligonucleotide therapeutic boom, manufacturers are discovering how to make critical raw materials—capping agents, lipid nanoparticles, and RNA polymerase—more effective.

Organometallic chemistry enables complex bond formation for pharmaceutical synthesis. Specialized cryogenic systems, closed handling, thermal control, and safety frameworks support reliable scale-up.

Uncover the key findings of a new wearable injector clinical trial, including its positive impact on patient experience and the broader benefits of wearable injectors for chronic disease management.

A highly concentrated non-aqueous suspension of an IgG1 was developed using a patented platform. Review how the particle size of the mAb impacts the overall behavior of the drug product.

Integrated stable expression strategies accelerate biologics material generation, improving scalability, consistency, and early developability insights while reducing bottlenecks and risks.